Table 1 Main characteristics of the enrolled studies

From: Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis

Study Study design Diagnosis Enrollment Interventions Course of treatment Primary outcome measures
Dodick et al. [12] Phase II Episodic migraine 190 subjects Galcanezumab 150 mg
Placebo
SC once every 14 days
12 weeks Mean change from baseline in the number of migraine headache days (MHD)
Skljarevski et al. [13] Phase IIb Episodic migraine 414 subjects Galcanezumab 5 mg/50 mg/120 mg/300 mg
Placebo
SQ once every 28 days
12 weeks Mean change from baseline in the number of MHD
Detke et al. [16] Phase III
(REGAIN)
Chronic migraine 1,113 subjects Galcanezumab 120 mg/240 mg
Placebo
SC once every 28 days
12 weeks Overall mean change from baseline in the number of monthly MHD
Stauffer et al. [14] Phase III
(EVOLVE-1)
Episodic migraine 862 subjects Galcanezumab 120 mg/240 mg
Placebo
SC once every 28 days
24 weeks Overall mean change from baseline in the number of monthly MHD
Skljarevski et al. [13] Phase III
(EVOLVE-2)
Episodic migraine 986 subjects Galcanezumab 120 mg/240 mg
Placebo
SC once every 28 days
24 weeks Overall mean change from baseline in the number of monthly MHD